Ptt 大爆卦 | SGLT1 - 前往 https://www.easd.org/virtualmeeting/home.html#!resources/the-intandem-2-study-52-week-efficacy-and-safety-of-sotagliflozin-a-dual-sglt1-and-sglt2-inhibitor-as-adjunct-therapy-to-insulin-in-adults-with-type-1-diabetes

你即將離開本站

並前往https://www.easd.org/virtualmeeting/home.html#!resources/the-intandem-2-study-52-week-efficacy-and-safety-of-sotagliflozin-a-dual-sglt1-and-sglt2-inhibitor-as-adjunct-therapy-to-insulin-in-adults-with-type-1-diabetes

The inTandem 2 study: 52-week efficacy and safety of ... - EASD

The inTandem 2 study: 52-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 ...

確定！回上一頁

查詢「SGLT1」的人也找了：

SGLT2 inhibitor